Actimmune oncology program ends
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
InterMune is discontinuing its oncology program for its biologic response modifier Actimmune (interferon gamma-1b) following negative results from a Phase III ovarian cancer trial, the firm says Feb. 2. The firm halted the GRACES trial in advanced ovarian cancer after Actimmune plus carboplatin and paclitaxel showed a significantly shorter overall survival than the two cytotoxic agents alone (39.7% vs. 30.4%, respectively; p=0.001). "The results from this study suggest that Actimmune…may exacerbate the dose-limiting toxicities of cytotoxic chemotherapy drugs. Consequently, we have no plans to initiate further studies of Actimmune in oncology or in combination with such chemotherapy regimens," InterMune said. Actimmune is indicated for chronic granulomatous disease and severe, malignant osteopetrosis...
You may also be interested in...
Israel's Gamida Cell Survives By Selling To Lender
Having finally secured US approval for Omisirge, Gamida was hoping to bag a strategic partner for the cell therapy. A year on, no suitable partner has been identified and the firm is delisting from the NASDAQ and going private.
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.